News - Advair, Kyorin Pharmaceuticals


Popular Filters

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay


The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Flutiform recommended for approval in Japan


UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Astellas and Ambrx collaborate in up to $300 oncology deal; Teijin takes stake in Kyorin


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with venture capital…

AmbrxAstellas PharmaKyorin PharmaceuticalsLicensingMergers & AcquisitionsOncologyPharmaceuticalTeijin

Great expectations for GlaxoSmithKline R&D newsflow


Essentially, analysts at Panmure Gordon & Co anticipate a lot of pipeline newsflow from UK pharma giant…


Asthma preventive drugs market led by GlaxoSmithKline's Advair


The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

Kyorin Pharma transfers Pekiron rights to Galderma


Japan's Kyorin Holdings (TYO: 4569), through its Kyorin Pharmaceuticals subsidiary, aiming to concentrate…

Asia-PacificDermatologicalsGaldermaKyorin PharmaceuticalsLicensingPekironPharmaceutical

New LABA/LAMA drugs set to fracture COPD market


The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

SkyePharma partner Kyorin files for Flutiform approval in Japan


UK drug delivery specialist SkyePharma (LSE: SKP) says that its Japanese development and marketing partner…

Asia-PacificFlutiformKyorin PharmaceuticalsNapp PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma partner Kyorin completes Japanese Flutiform clinical program


UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Relovair COPD and asthma filings on track despite more mixed trial results


As well as announcing new mixed clinical trial data, UK pharma giant GlaxoSmithKline (LSE: GSK) and US…

AdvairEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRelovairRespiratory and PulmonaryTheravance

Back to top